HIV-1 entry into CD4+ T cells requires binding of the virus to CD4 followed by engagement of either the CCR5 or CXCR4 coreceptor. Pharmacologic blockade or genetic inactivation of either coreceptor protects cells from infection by viruses that exclusively use the targeted coreceptor. We have used zinc-finger nucleases to drive the simultaneous genetic modification of both ccr5 and cxcr4 in primary human CD4+ T cells. These gene-modified cells proliferated normally and were resistant to both CCR5-and CXCR4-using HIV-1 in vitro. When introduced into a humanized mouse model of HIV-1 infection, these coreceptor negative cells engraft and traffic normally, and are protected from infection with CCR5-and CXCR4-using HIV-1 strains. These data suggest that simultaneous disruption of the HIV coreceptors may provide a useful approach for the long-term, drug free treatment of established HIV-1 infections.
Introduction
Potent antiretroviral therapy (ART) suppresses circulating levels of HIV to below the limit of detection, dramatically delaying progression to AIDS 1, 2 . However, the side effects, cost, daily adherence requirement, and immune dysfunction that persists despite ART, underscore the need for strategies to suppress HIV infection and reconstitute immune function without ART [1] [2] [3] [4] [5] . One approach involves rendering CD4+ T cells resistant to HIV by permanent inactivation of the viral entry receptors. To enter a cell, HIV must bind its primary receptor CD4, and one of two coreceptors, CCR5 (R5) or CXCR4 (X4) [6] [7] [8] [9] [10] [11] [12] [13] . The majority of transmitted viruses use R5 to enter cells [14] [15] [16] while X4-using viruses are seen in half of late-stage infections 17, 18 , and are associated with a more rapid disease progression 19, 20 . Individuals lacking functional R5 due to the naturally occurring ccr5∆32 mutation are highly resistant to HIV infection [21] [22] [23] , and
recently, an HIV-positive male who received a bone marrow transplant from a ccr5∆32
homozygous donor appears to be cured of HIV 24, 25 . As allogeneic stem cell transplants prior to this case have not had any effect on HIV infection 26, 27 , the response seen in this patient highlights the importance of the coreceptors in maintaining HIV infection, and supports the idea that permanent coreceptor inactivation in infected individuals may provide drug-free control of HIV.
In this study, we have used zinc finger nucleases (ZFNs) to simultaneously inactivate the ccr5 and cxcr4 genes. ZFNs are chimeric proteins that function as a pair and act in a sequence-specific manner to introduce a double-stranded break (DSB) at a predetermined site in the genome 28 . As these DSBs are often repaired by error-prone non-homologous end-joining 29 , ZFN cleavage introduces mutations that produce
For personal use only. on . by guest www.bloodjournal.org From 4 truncated or non-functional proteins. The use of ZFNs to target the coreceptors is particularly attractive, as ZFNs need only be transiently expressed, and generate stable, heritable mutations in target cells. We and others have shown that permanent inactivation of ccr5 or cxcr4 alone can be achieved in CD4+ T cells and protects from infection with viruses that exploit the targeted coreceptor [30] [31] [32] [33] . Additionally, a recent phase 1 study examining the safety of R5-ZFN modified CD4+ T cells in HIV-infected individuals showed that not only is this approach safe and well tolerated, but that these gene-modified cells are long-lived and capable of trafficking to the rectal mucosa-a major site of HIV replication (Carl H. June, University of Pennsylvania, written communication, May 23, 2013) . To make this approach more broadly applicable to patients with both R5 and X4-HIV, we sought to determine the feasibility of simultaneous modification of both HIV coreceptors in CD4+ T cells by ZFNs, and its effect on HIV infection.
Methods

Cell culture and ZFN treatment. SupT1 T cells expressing multiple copies of CCR5
introduced by lentiviral transduction (SupT1-R5), and primary human CD4+ T cells were maintained in RPMI (Invitrogen) supplemented with 10% fetal bovine serum (FBS).
CD4+ T cells were grown in the presence of human IL-2 (100 IU/ml). We used R5 and X4 zinc finger proteins (ZFPs) from our previous studies 31, 32 . However, the ZFN nuclease domains were the ELD/KKR variant which were modified to function as obligate heterodimers with enhanced cleavage activity 34 . Off-target site analysis. We previously used systematic evolution of ligands by exponential enrichment (SELEX) to determine the in vitro binding preference of each zinc finger protein (ZFP) 31, 32 . Using the information on CCR5 and CXCR4 binding preferences, we generated a position-weight matrix which we aligned to the human genome to look for sites with similarity to each of the four possible combinations of CCR5-CXCR4 cross heterodimers (R5-left with X4-right; R5-left with X4-left; R5-right with X4-right; R5-right with X4-left). We allowed up to a 4bp mismatch compared to the SELEX consensus sequence, and considered sites with a 5bp or 6bp spacer between each ZFP pair. We performed deep sequencing at these sites to identify off-target encoding GFP had no effect on surface R5 or X4 levels ( Figures 1A-B) . Next, we assessed the ability of ccr5 and cxcr4 co-disruption to protect cells from infection with R5 and X4-using HIV-1 strains. We challenged untreated or R5/X4-ZFN treated SupT1- expression into CXCR4-high and CXCR4-low populations ( Figure 2C ). We then measured levels of R5 and X4 gene modification in both of these populations. While cxcr4 gene modification was greatly reduced in the X4-high population following sorting, levels of ccr5 modification were similar in the X4-high and X4-low populations ( Figure   2D ), suggesting that adenoviral dual-ZFN treatment achieved dual-modification of ccr5
and cxcr4 in primary CD4+ T cells. suggesting that we can effectively target the coreceptors in these critically important T cell subsets.
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Survival advantage of dual-ZFN treated CD4+ T cells in vitro
To determine if the level of gene modification seen in primary cells rendered them resistant to both forms of HIV-1, we treated CD4+ T cells with both ZFNs, the R5-ZFN alone, or with a GFP control. We then challenged all three groups with a mix of R5-and X4-using HIV-1 and monitored cell growth and viability. By 32 days post-infection, there were no detectable live cells in the groups that received either no ZFN or the R5-ZFN alone, whereas cells from the R5/X4 ZFN group continued to expand ( Figure 3A ).
We measured levels of ccr5 and cxcr4 gene modification 3 weeks into the infection in the R5/X4-ZFN treated group and observed increases in both ccr5 (1.8-fold) and cxcr4 , we previously determined the in vitro DNA binding preference of each CCR5 and CXCR4 ZFP using SELEX 31, 32 . We constructed a position-weight matrix for . In this study, we took a similar approach to identify off target sites that could result from the binding and cleavage of a ZFN heterodimer consisting of one half R5-ZFN and one-half X4-ZFN. We performed deep sequencing at these predicted sites in primary CD4+ T cells following treatment with both the R5-and X4-ZFNs compared to otherwise identical untransduced controls (Supplementary table 1) . Using genomic DNA from samples where on-target modification of ccr5 and cxcr4 were 28% and 20% respectively, we analyzed 4,000-20,000 reads per predicted off-target site but failed to detect significant levels of modification at any of the 40 predicted off-target sites (Supplementary Table 1 ). These results suggests that cross-heterodimerization of the R5-and X4-ZFN pairs following delivery to primary CD4+ T cells does not result in detectable off-target activity, at the 40 sites examined. Moreover, the use of recently described orthogonal heterodimeric nuclease domains that further restrict cleavage 45 could further address this concern.
Dual coreceptor disruption protects CD4+ T cells following HIV infection in vivo
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( Figure 4A ). We observed CD4+ T cell engraftment across all groups 21 days postinfusion ( Figure 4B ).We then infected half the animals in each group by simultaneously Figure 4D ). This slight engraftment difference was not seen previously 31, 32 and may be donor specific. While CCR5 ablation alone was previously shown to protect against challenge with CCR5-using HIV 31 , animals that received both ZFNs were better able to maintain their CD4+ T cell counts following challenge with R5-and X4-HIV ( Figure 4D ). Specifically, CD4 counts in animals from the infected R5/X4-ZFN group were 35 and100-fold higher than those in animals from the mock and R5-ZFN infected groups respectively by 22 days post-infection, and these differences increased to an average 200-fold difference 55 days post infection ( Figure   4D ). Additionally, we measured the proportion of human CD4+ T cells in the spleens of infected animals at time of sacrifice. In animals that received dual-ZFN treated cells, up
to 10% of all cells populating the spleen were human CD4+ T cells whereas we could not detect any human CD4+ T cells in spleens from animals that received either no ZFN or the R5-ZFN alone ( Figure 4C ).
To determine the mechanism of CD4 count maintenance observed in the R5/X4-ZFN group, we performed deep sequencing at the ZFN cut-sites in CD4+ T cells from animals in the R5/X4-ZFN group to measure changes in the proportion of ZFN-induced indels. There was no change in ccr5 or cxcr4 gene modification in uninfected animals that received both ZFNs. However, on average, 69% of all ccr5 genes and 73% of all cxcr4 genes were mutated in CD4+ T cells from the infected R5/X4-ZFN animals by 34 days post-infection ( Figure 5A ). This represents a 2.2-fold increase in ccr5-modification and a 2.3-fold increase in cxcr4-modification compared to six days post-infection.
Additionally, we observed significantly lower surface expression of both coreceptors on cells from the infected R5/X4-ZFN treated mice 34 days post-infection ( Figure 5B ).
These data provide strong evidence that simultaneous disruption of ccr5 and cxcr4
using ZFNs is capable of generating a pool of cells that are resistant to the major forms of HIV in vivo, and these cells can engraft, traffic normally to the spleen, and have a significant survival advantage in the presence of R5-and X4-using HIV.
Discussion
Genetic approaches to control HIV infection have so far involved the removal of host genes required by the virus, or the introduction of antiviral genes that interfere with virus replication 48, 49 . While both are attractive options, the latter approach could be hampered by the potential immunogenicity of foreign transgenes and the diversity of the For This work was funded by the following grant: NIH U19 AI082628.
For by preservation of peripheral blood CD4+ T cell counts. All uninfected animals and 1 infected animal in the R5/X4-ZFN treated group were euthanized 34 days post infection due xenogeneic graft-versus-host disease. Infected animals were followed for 55 days after infection. All statistical analyses were performed using a Mann-Whitney U test.
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